Argenx's CEO on using FcRn to target IgG mediated autoimmune diseases
- blonca9
- Jan 9, 2024
- 1 min read
Tim Van Hauwermeiren describes the science behind argenx's success, the potential market potential, pipeline programs, and his thoughts on European biotech.
